Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
08 janv. 2024 10h59 HE
|
Recursion Pharmaceuticals
SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration...
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
03 janv. 2024 08h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Chris...
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
20 déc. 2023 07h59 HE
|
Recursion Pharmaceuticals
KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today...
Bayer and Recursion Focus Research Collaboration on Oncology
09 nov. 2023 09h41 HE
|
Recursion Pharmaceuticals
Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug...
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
09 nov. 2023 07h58 HE
|
Recursion Pharmaceuticals
Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion’s proprietary...
Recursion to Participate in Upcoming Investor Conference
02 nov. 2023 08h05 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conferences
05 sept. 2023 16h30 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
05 sept. 2023 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
08 août 2023 08h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
08 août 2023 07h58 HE
|
Recursion Pharmaceuticals
Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world’s...